CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013

Neuro-Oncology

Volumn 18, Issue , 2016, Pages v1-v75

  Ostrom, Quinn T ^a,b   Gittleman, Haley ^a,b   Xu, Jordan ^a   Kromer, Courtney ^c   Wolinsky, Yingli ^a,b   Kruchko, Carol ^b   Barnholtz Sloan, Jill S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Central Brain Tumor Registry of the United States   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASTROCYTOMA; BEHAVIOR; BLACK PERSON; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD; CONTROLLED STUDY; EMBRYONAL TUMOR; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; FACTUAL DATABASE; FEMALE; GEOGRAPHIC DISTRIBUTION; GLIOBLASTOMA; GLIOMA; HISPANIC; HISTOPATHOLOGY; HUMAN; HYPOPHYSIS TUMOR; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MORBIDITY; NERVE SHEATH TUMOR; PRIMARY TUMOR; RACE DIFFERENCE; SEX DIFFERENCE; SPINAL CORD TUMOR; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; TREND STUDY; TUMOR LOCALIZATION; UNITED STATES; YOUNG ADULT; EPIDEMIOLOGICAL MONITORING; INFANT; NEWBORN; ORGANIZATION; PRESCHOOL CHILD; REGISTER;

ADOLESCENT; ADULT; BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; REGISTRIES; SOCIETIES; UNITED STATES; YOUNG ADULT;

EID: 84995678253     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now207     Document Type: Article

References (76)

1. Centers for Disease Control and Prevention (CDC). National Program of Cancer Registries Cancer Surveillance System Rationale and Approach. 1999; http://www.cdc.gov/cancer/npcr/pdf/npcr-css.pdf.
2. Cancer Registries Amendment Act, 102nd Cong. 515 1992; http://www.gpo.gov/fdsys/pkg/STATUTE-106/pdf/STATUTE-106-Pg3372.pdf.
3. Benign Brain Tumor Cancer Registries Amendment Act, 107th Cong. 260 2002; http://www.gpo.gov/fdsys/pkg/PLAW-107publ260/pdf/PLAW-107publ260.pdf.
4. National Cancer Institute. Overview of the SEER Program. http://seer.cancer.gov/about/overview.html.
5. Wohrer A, Waldhor T, Heinzl H,, et al. The Austrian brain tumour registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol. 2009;95(3):401-411
6. Asklund T, Malmstrom A, Bergqvist M,, et al. Brain tumors in Sweden: data from a population-based registry 1999-2012. Acta Oncol. 2015;54(3):377-384.
7. Centers for Disease Control and Prevention National Center for Health Statistics. United States Cancer Statistics: 1999-2013 Incidence, WONDER Online Database. United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2016; Accessed at http://wonder.cdc.gov/cancer-v2013.HTML.
8. Louis D, Wiestler O, Cavanee W, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007.
9. Ostrom QT, Gittleman H, Liao P,, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(s4): iv1-iv63.
10. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Perkin DM, Whelan S ed International Classification of Diseases for Oncology, Third edition. World Health Organization; 2000.
11. Surveillance Research Program-National Cancer Institute. SEER as a Research Resource. 2010; http://seer.cancer.gov/about/factsheets/SEER-Research-Brochure.pdf.
12. Surveillance Epidemiology and End Results (SEER) Program. SEERStat Database: Mortality-All COD, Aggregated With State, Total U.S. (1969-2013) , National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).
13. McCarthy BJ, Surawicz T, Bruner JM,, et al. Consensus conference on brain tumor definition for registration. November 10, 2000. Neuro Oncol. 2002;4(2):134-145.
14. Kleihues P, Cavenee W, eds. Tumours of the nervous system: World Health Organization classification of tumours. Lyon, France: IARC Press; 2000.
15. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, ed WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2016.
16. American Joint Committee on Cancer. Collaborative Stage Data Collection System. 2015; http://www.cancerstaging.org/cstage/.
17. Lym RL, Ostrom QT, Kruchko C,, et al. Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. J neurooncol. 2015;123(1):43-51.
18. Surveillance Research Program-National Cancer Institute. ICCC Recode ICD-O-3/WHO 2008. http://seer.cancer.gov/iccc/icccwho2008. html.
19. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103:1457-1467.
20. Surveillance Research Program-National Cancer Institute. ICD-0-3 SEER Site/Histology Validation List. 2012; http://seer.cancer. gov/icd-o-3/sitetype.icdo3.d20121205.pdf.
21. R Core Team. R: A language and environment for statistical computing. 2016; http://www.R-project.org/.
22. Surveillance Epidemiology and End Results (SEER) Program. SEERStat software version 8.3.2. 2016; www.seer.cancer.gov/seerstat.
23. Bivand R, Rundel C. rgeos: Interface to Geometry Engine-Open Source (GEOS). R package version 0.3-11. 2015; http://CRAN.Rproject. org/package=rgeos.
24. Bivand R, Keitt T, Rowlingson B. rgdal: Bindings for the Geospatial Data Abstraction Library. R package version 1.0-4. 2015; http://CRAN.R-project.org/package=rgdal.
25. Bivand R, Lewin-Koh N. maptools: Tools for Reading and Handling Spatial Objects. R package version 0.8-36. 2015; http://CRAN.Rproject. org/package=maptools.
26. Wickham H. ggplot2: elegant graphics for data analysis. 2009; http://had.co.nz/ggplot2/book.
27. Lemon J. Plotrix: a package in the red light district of R. R-News. 2006;6(4):8-12.
28. Luo J. SEER2R: reading and writing SEERSTAT data files. R package version 1.0. 2012; http://CRAN.R-project.org/package=SEER2R.
29. Surveillance Epidemiology and End Results (SEER) Program. SEERStat Database: Populations-Total U.S. (1990-2014)-Linked To County Attributes-Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released October 2015; http://seer. cancer.gov/popdata/.
30. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-Adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547-569.
31. NAACCR Race and Ethnicity Work Group. NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. . September 2012.
32. Joinpoint Regression Program, Version 4.2.0-April 2015; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
33. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335-351.
34. Zhu L, Pickle LW, Ghosh K,, et al. Predicting US-And state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer. 2012;118:1100-1109.
35. Centers for Disease Control and Prevention National Center for Health Statistics. Underlying Cause of Death 1999-2014 on CDC WONDER Online Database, released 2016. Data are from the Multiple Cause of Death Files, 1999-2014, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http://wonder.cdc.gov/ucd-icd10.html.
36. Surveillance Epidemiology and End Results (SEER) Program. SEERStat Database: Incidence-SEER 18 Regs Research Data +Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)-Linked To County Attributes-Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
37. Edwards BK, Noone AM, Mariotto AB,, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290-1314.
38. Zullig LL, Jackson GL, Dorn RA,, et al. Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med. 2012;177:693-701.
39. Clegg LX, Feuer EJ, Midthune DN,, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20):1537-1545. http://www.ncbi.nlm.nih. gov/pubmed/12381706.
40. Midthune DN, Fay MP, Clegg LX, Feuer EJ. Modeling reporting delays and reporting corrections in cancer registry data. J Am Stat Assoc. 2005;100(469):61-70.
41. Surveillance Epidemiology and End Results (SEER) Program. Cancer Incidence Rates Adjusted for Reporting Delay. 2016; http://surveillance.cancer.gov/delay/.
42. Ostrom QT, de Blank PM, Kruchko C,, et al. Alex?s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2015;16(Suppl 10):x1-x36.
43. Gurney JG, Smith M, Bunin GR. Chapter III: CNS and miscellaneous intracranial and intraspinal neoplasms. In: Ries LAG, Smith M, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR ed. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. . NIH Pub. No. 99-4649. Bethesda, MD; 1999.
44. de Blank PM, Ostrom QT, Rouse C,, et al. Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. Cancer Med. 2015;4(4):608-619.
45. National Cancer Institute at the National Institutes of Health. Adolescents and Young Adults with Cancer. http://www.cancer. gov/cancertopics/aya.
46. Ostrom QT, Gittleman H, de Blank PM,, et al. American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2016;18(Suppl 1):i1-i50.
47. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.
48. McCarthy BJ, Kruchko C, Dolecek TA. The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260) on Non-malignant brain and central nervous system tumor incidence trends. J Registry Manag. 2013;40(1):32-35.
49. Kshettry VR, Ostrom QT, Kruchko C,, et al. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015;17(8):1166-1173.
50. Braganza MZ, Kitahara CM, Berrington de Gonzalez A,, et al. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316-1324.
51. Turner MC. Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother. 2012;61:1493-1510.
52. Ostrom QT, Bauchet L, Davis FG,, et al. The epidemiology of glioma in adults: a ?state of the science? review. Neuro Oncol. 2014;16:896-913.
53. Johnson KJ, Cullen J, Barnholtz-Sloan JS,, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev.2014;23(12):2716-2736.
54. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307-314
55. Cairncross JG, Ueki K, Zlatescu MC,, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
56. Cairncross G, Wang M, Shaw E,, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-Term results of RTOG 9402. J Clin Oncol. 2013;31(3):337-343.
57. Vogelbaum MA, Hu C, Peereboom DM,, et al. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol. 2015;124(3):413-420.
58. van den Bent MJ, Brandes AA, Taphoorn MJ,, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-Term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344-350.
59. Yan H, Parsons DW, Jin G,, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
60. Ceccarelli M, Barthel FP, Malta TM,, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164(3):550-563.
61. The Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG,, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481-2498.
62. Hegi ME, Diserens AC, Gorlia T,, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
63. Hegi ME, Liu L, Herman JG,, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189-4199.
64. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007;25:4127-4136.
65. Noushmehr H, Weisenberger DJ, Diefes K,, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-522.
66. van den Bent MJ, Erdem-Eraslan L, Idbaih A,, et al. MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res. 2013;19:5513-5522.
67. Kool M, Korshunov A, Remke M,, et al. Molecular subgroups of medulloblastoma: an international meta-Analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473-484.
68. Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother. 2012;12:871-884.
69. Northcott PA, Jones DT, Kool M,, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12:818-834.
70. Ostrom QT, Gittleman H, Kruchko C,, et al. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). J Neurooncol. 2016.
71. Weir HK, Johnson CJ, Mariotto AB,, et al. Evaluation of North American Association of Central Cancer Registries? (NAACCR) data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr. 2014;2014:198-209.
72. Wilson RJ, O?Neil ME, Ntekop E,, et al. Coding completeness and quality of relative survival-related variables in the National Program of Cancer Registries Cancer Surveillance System, 1995-2008. J Registry Manag. 2014;41(2):65-71; quiz 96-67.
73. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255-268.
74. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician?s perspective. Acta Neuropathol. 2010;120:297-304.
75. Aldape K, Simmons ML, Davis RL,, et al. Discrepancies in diagnoses of neuroepithelial neoplasms: the San Francisco Bay Area Adult Glioma Study. Cancer. 2000;88:2342-2349.
76. Sahm F, Reuss D, Koelsche C,, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551-559.